Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, Unit 1465, Houston, TX 77230-1402, USA.
Cardiol Res Pract. 2011;2011:816897. doi: 10.4061/2011/816897. Epub 2011 May 10.
Frequently, primary care providers continue to manage the overall medical care of cancer patients. With newer and often more potent antitumor agents, patients may present to their local physicians with drug-induced toxicities such as hypertension induced by vascular endothelial growth factor (VEGF) inhibitors. It is imperative that these healthcare providers are aware of basic aspects of this drug class, as its use has increased significantly in the last several years. Uncontrolled or malignant hypertension due to these agents should be recognized readily and treated early to prevent more severe outcomes. This overview provides a brief background on the role of VEGF and angiogenesis in tumor metabolism as well as theories of the mechanism of VEGF inhibitors and hypertension. Helpful clinical practice aspects including the types of inhibitors used in the United States and their pharmacologic characteristics will be discussed. Also, diagnosis and treatment of hypertension induced by vascular endothelial growth factors are reviewed. A summary of key aspects of this drug class and hypertension is included.
通常，初级保健提供者会继续管理癌症患者的整体医疗护理。随着新型且通常更有效的抗肿瘤药物的出现，患者可能会因药物引起的毒性而向当地医生就诊，例如血管内皮生长因子 (VEGF) 抑制剂引起的高血压。这些医疗保健提供者必须了解此类药物的基本方面，因为近年来其使用量显著增加。由于这些药物引起的不受控制或恶性高血压应及早识别并及早治疗，以防止出现更严重的后果。本文简要概述了 VEGF 和血管生成在肿瘤代谢中的作用，以及 VEGF 抑制剂和高血压的作用机制理论。将讨论有助于临床实践的方面，包括在美国使用的抑制剂类型及其药理学特征。还将对 VEGF 引起的高血压的诊断和治疗进行综述。本文还总结了此类药物和高血压的关键方面。
